



October 26, 2009

Zafgen, Inc. to Present at Upcoming Conferences

CAMBRIDGE, MA, October 26, 2009 –Zafgen, Inc., a private venture-backed biopharmaceutical company focused on developing novel obesity therapeutics, today announced that management will present at two upcoming conferences:

- Matthias Jaffe, chief financial officer and vice president of business development, will present at the 2009 Boston Biotech Research and Development Conference, in Boston at the Joseph B. Martin Conference Center at Harvard Medical School, on October 27, 2009 at 1:40-2:00 p.m.; and
- Thomas Hughes, Ph.D., president and chief executive officer, will present at Windhover's Therapeutic Area Partnerships, in Boston at Westin Copley Place, on November 18 at 2:00-2:15 p.m. Zafgen was named one of the Top 10 Projects to Watch in the cardiovascular/metabolic therapeutic area by Elsevier Business Intelligence and Windhover Conferences for this event.

About Zafgen, Inc.

Zafgen is the first biopharmaceutical company dedicated to developing novel obesity therapeutics that directly target and shrink fat tissue to help the body regain and sustain a lean, healthy state. Adipose tissue (fat) is composed primarily of cells that store unused calories, as well as an extensive network of blood vessels that support the tissue. The nature of the tissue and the interplay between fat cells and the supporting blood vessels play a critical and active role in determining the overall size of the fat tissue, and therefore, an individual's weight. Zafgen's groundbreaking approach targets obesity at its root cause by safely manipulating and shrinking the blood supply to fat tissue, driving the loss of fat and a return to a more healthy body weight. Zafgen's leadership and scientific advisors include the leading experts in obesity, metabolic disorders and medicinal chemistry. Founded in 2005, the company is located in Cambridge, Massachusetts. For more information, visit www.zafgen.com.